Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa)
Phase: 2
Status: Not Enrolling
Details
Alvelestat (MPH996) for the Treatment of Alpha-1 Antitrypsin Deficiency (ATLANTa) – A Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of Alvelestat (MPH996) in alpha-1 antitrypsin deficiency
Sponsor: Mereo
IRB#: 1090
